Bausch Health Companies Inc
TSX:BHC

Watchlist Manager
Bausch Health Companies Inc Logo
Bausch Health Companies Inc
TSX:BHC
Watchlist
Price: 11.17 CAD -2.45% Market Closed
Market Cap: 4.1B CAD
Have any thoughts about
Bausch Health Companies Inc?
Write Note

Intrinsic Value

The intrinsic value of one BHC stock under the Base Case scenario is 111.27 CAD. Compared to the current market price of 11.17 CAD, Bausch Health Companies Inc is Undervalued by 90%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BHC Intrinsic Value
111.27 CAD
Undervaluation 90%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Bausch Health Companies Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for BHC cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about BHC?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Bausch Health Companies Inc

Provide an overview of the primary business activities
of Bausch Health Companies Inc.

What unique competitive advantages
does Bausch Health Companies Inc hold over its rivals?

What risks and challenges
does Bausch Health Companies Inc face in the near future?

Summarize the latest earnings call
of Bausch Health Companies Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Bausch Health Companies Inc.

Provide P/S
for Bausch Health Companies Inc.

Provide P/E
for Bausch Health Companies Inc.

Provide P/OCF
for Bausch Health Companies Inc.

Provide P/FCFE
for Bausch Health Companies Inc.

Provide P/B
for Bausch Health Companies Inc.

Provide EV/S
for Bausch Health Companies Inc.

Provide EV/GP
for Bausch Health Companies Inc.

Provide EV/EBITDA
for Bausch Health Companies Inc.

Provide EV/EBIT
for Bausch Health Companies Inc.

Provide EV/OCF
for Bausch Health Companies Inc.

Provide EV/FCFF
for Bausch Health Companies Inc.

Provide EV/IC
for Bausch Health Companies Inc.

Show me price targets
for Bausch Health Companies Inc made by professional analysts.

What are the Revenue projections
for Bausch Health Companies Inc?

How accurate were the past Revenue estimates
for Bausch Health Companies Inc?

What are the Net Income projections
for Bausch Health Companies Inc?

How accurate were the past Net Income estimates
for Bausch Health Companies Inc?

What are the EPS projections
for Bausch Health Companies Inc?

How accurate were the past EPS estimates
for Bausch Health Companies Inc?

What are the EBIT projections
for Bausch Health Companies Inc?

How accurate were the past EBIT estimates
for Bausch Health Companies Inc?

Compare the revenue forecasts
for Bausch Health Companies Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Bausch Health Companies Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Bausch Health Companies Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Bausch Health Companies Inc compared to its peers.

Compare the P/E ratios
of Bausch Health Companies Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Bausch Health Companies Inc with its peers.

Analyze the financial leverage
of Bausch Health Companies Inc compared to its main competitors.

Show all profitability ratios
for Bausch Health Companies Inc.

Provide ROE
for Bausch Health Companies Inc.

Provide ROA
for Bausch Health Companies Inc.

Provide ROIC
for Bausch Health Companies Inc.

Provide ROCE
for Bausch Health Companies Inc.

Provide Gross Margin
for Bausch Health Companies Inc.

Provide Operating Margin
for Bausch Health Companies Inc.

Provide Net Margin
for Bausch Health Companies Inc.

Provide FCF Margin
for Bausch Health Companies Inc.

Show all solvency ratios
for Bausch Health Companies Inc.

Provide D/E Ratio
for Bausch Health Companies Inc.

Provide D/A Ratio
for Bausch Health Companies Inc.

Provide Interest Coverage Ratio
for Bausch Health Companies Inc.

Provide Altman Z-Score Ratio
for Bausch Health Companies Inc.

Provide Quick Ratio
for Bausch Health Companies Inc.

Provide Current Ratio
for Bausch Health Companies Inc.

Provide Cash Ratio
for Bausch Health Companies Inc.

What is the historical Revenue growth
over the last 5 years for Bausch Health Companies Inc?

What is the historical Net Income growth
over the last 5 years for Bausch Health Companies Inc?

What is the current Free Cash Flow
of Bausch Health Companies Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Bausch Health Companies Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Bausch Health Companies Inc

Current Assets 5.4B
Cash & Short-Term Investments 719m
Receivables 2.1B
Other Current Assets 2.5B
Non-Current Assets 21.2B
PP&E 1.8B
Intangibles 16.8B
Other Non-Current Assets 2.6B
Current Liabilities 4.5B
Accounts Payable 667m
Accrued Liabilities 3.3B
Other Current Liabilities 555m
Non-Current Liabilities 23.2B
Long-Term Debt 21.1B
Other Non-Current Liabilities 2.2B
Efficiency

Earnings Waterfall
Bausch Health Companies Inc

Revenue
9.5B USD
Cost of Revenue
-2.8B USD
Gross Profit
6.7B USD
Operating Expenses
-5B USD
Operating Income
1.7B USD
Other Expenses
-1.9B USD
Net Income
-178m USD

Free Cash Flow Analysis
Bausch Health Companies Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Bausch Health celebrated its sixth consecutive quarter of growth with revenues climbing 7% and adjusted EBITDA rising 9% year-over-year. With Q3 revenues reaching approximately $2.51 billion, the company cited a notable 75% increase in adjusted cash flow to $343 million. The strong performance led to an optimistic raise in the 2024 guidance: projected revenue now sits between $4.775 billion and $4.85 billion, with organic growth revised to 4%-6%. Additionally, adjusted EBITDA guidance is now estimated at $2.425 billion to $2.475 billion, showing resilience across all segments, particularly in Salix and the Solta business.

What is Earnings Call?
Fundamental Scores

BHC Profitability Score
Profitability Due Diligence

Bausch Health Companies Inc's profitability score is 52/100. The higher the profitability score, the more profitable the company is.

52/100
Profitability
Score

Bausch Health Companies Inc's profitability score is 52/100. The higher the profitability score, the more profitable the company is.

BHC Solvency Score
Solvency Due Diligence

Bausch Health Companies Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Positive Net Debt
42/100
Solvency
Score

Bausch Health Companies Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BHC Price Targets Summary
Bausch Health Companies Inc

Wall Street analysts forecast BHC stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BHC is 10.46 CAD with a low forecast of 9.6 CAD and a high forecast of 11.55 CAD.

Lowest
Price Target
9.6 CAD
14% Downside
Average
Price Target
10.46 CAD
6% Downside
Highest
Price Target
11.55 CAD
3% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for BHC?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for BHC is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

BHC News

Other Videos

Profile

Bausch Health Companies Inc Logo
Bausch Health Companies Inc

Country

Canada

Industry

Pharmaceuticals

Market Cap

4.1B CAD

Dividend Yield

0%

Description

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. The company is headquartered in Laval, Quebec and currently employs 19,600 full-time employees. The firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. Its segments include Bausch + Lomb, Salix, Ortho Dermatologics, International Rx and Diversified Products. The Bausch + Lomb segment consists of sales in the United States of Bausch + Lomb Vision Care, Consumer, Surgical and Ophthalmology Rx products. The Salix segment consists of sales in the United States of gastroenterology (GI) products. The Ortho Dermatologics segment consists of sales in the United States of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices.

Contact

QUEBEC
Laval
2150 Saint-Elzear Blvd W
+18003611448.0
www.bauschhealth.com

IPO

1994-09-20

Employees

19 600

Officers

CEO & Director
Mr. Thomas J. Appio
Executive VP & General Counsel
Ms. Seana Carson
Executive VP & CFO
Mr. Jean-Jacques Charhon
Executive VP & COO
Mr. Mirza Dautbegovic
Executive VP and Chief HR & Communications Officer
Ms. Kathleen Fitzpatrick
Senior Vice President of Europe & Canada
Mr. Cees Heiman
Show More
Senior Vice President of Ortho Dermatologics
Mr. Donald Pearl
Senior Vice President of Solta Medical
Ms. Jiny Kim M.B.A.
Executive Vice President of US Pharma
Ms. Aimee J. Lenar
Senior VP & Treasurer
William N. Woodfield
Show Less

See Also

Discover More
What is the Intrinsic Value of one BHC stock?

The intrinsic value of one BHC stock under the Base Case scenario is 111.27 CAD.

Is BHC stock undervalued or overvalued?

Compared to the current market price of 11.17 CAD, Bausch Health Companies Inc is Undervalued by 90%.

Back to Top